Largo company starts clinical trials on Covid-19 screening device
May 26, 2020 - Kaligia Biosciences is starting clinical trials of its Rapid Biofluid Analyzer 2, a portable, saliva-based device that can screen for COVID-19 and can produce results in less than three minutes. The company's new device is based on the technology in an earlier product that analyses multiple blood components. Kaligia Biosciences is collaborating with AdventHealth, the University of South Florida College of Pharmacy, the USF College of Medicine and Tampa General Hospital to adapt the device for COVID-19 screening. The technology is non-invasive, more accessible and faster than COVID-19 tests that currently require nasal swabs or blood samples, and can take days, if not weeks to obtain results, Fazal Fazlin, Kaligia CEO, said in a news release.